Skip to main content
H.R. 6832 117th Congress House

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies,…

Official title: To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key t… Show full official titleShow less

Official title: To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Introduced: February 25, 2022 Introduced by: Michael Cloud Republican · Texas See on congress.gov
Health Cardiovascular and respiratory healthDrug safety, medical device, and laboratory regulationDrug therapyEmergency medical services and trauma care
More subjectsShow fewer subjects
Health care coverage and accessHealth programs administration and fundingHealth technology, devices, suppliesInfectious and parasitic diseasesIntergovernmental relationsMilitary procurement, research, weapons developmentPresidents and presidential powers, Vice PresidentsPublic contracts and procurementState and local government operations
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 28, 2022
Referred to the Subcommittee on Health.
Feb 25, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 25, 2022
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 28, 2022

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

This bill restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19.

Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritize the performance of federal contracts or orders for COVID-19 supplies over the performance of state or territorial contracts or orders. In addition, states or territories may use federal COVID-19 relief funds for COVID-19 supplies that they had been unable to purchase because of prioritized performance of federal contracts or orders. (The Defense Production Act of 1950 confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense.)

Additionally, the Food and Drug Administration may not ration, limit, restrict access to, or otherwise control the quantity of a medical product authorized for use during an emergency, including by requiring products to be distributed through a state- or territorial-based system.

 Related & companion bills 1
  • S 3440 Identical bill A bill to amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal…
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
 Lobbying activity 18

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • PET FOOD INSTITUTE
    for PET FOOD INSTITUTE · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • BASF CORPORATION
    for BASF CORPORATION · New Jersey · 3rd Quarter 2026 (July 1 - Sep 30)
  • CONAGRA BRANDS, INC.
    for CONAGRA BRANDS INC · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • THE PERSONAL CARE PRODUCTS COUNCIL
    for PERSONAL CARE PRODUCTS COUNCIL · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • AMERICAN CLEANING INSTITUTE
    for AMERICAN CLEANING INSTITUTE (FORMERLY KNOWN AS THE SOAP & DETERGENT ASSOCIATION) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
  • LYONDELL CHEMICAL COMPANY
    for LYONDELL CHEMICAL COMPANY · Texas · 3rd Quarter 2026 (July 1 - Sep 30)

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 18 filings →
 Cosponsors 6
All 6 Republican 5
Brooks, Mo
· Feb 28, 2022
 R
Biggs, Andy
Arizona · Feb 25, 2022
 R
Donalds, Byron
Florida · Feb 25, 2022
 R
Miller, Mary E.
Illinois · Feb 25, 2022
 R
Tiffany, Thomas P.
Wisconsin · Feb 25, 2022
 R
Webster, Daniel
Florida · Feb 25, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6832: To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.. 117th Congress. Open America. https://openamerica.io/bill/117-HR-6832/
MLA
"H.R. 6832: To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-6832/.
Bluebook (legal)
H.R. 6832, 117th Cong. (2026), https://openamerica.io/bill/117-HR-6832/.
Markdown link
[H.R. 6832: To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.](https://openamerica.io/bill/117-HR-6832/)
Report a problem